Russell Investments Group Ltd. lessened its position in shares of Cambrex Co. (NYSE:CBM) by 23.3% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 44,565 shares of the biotechnology company’s stock after selling 13,541 shares during the period. Russell Investments Group Ltd. owned approximately 0.14% of Cambrex worth $2,451,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors have also recently bought and sold shares of the stock. Stifel Financial Corp increased its holdings in Cambrex by 0.8% during the 2nd quarter. Stifel Financial Corp now owns 4,580 shares of the biotechnology company’s stock worth $275,000 after acquiring an additional 37 shares during the period. YorkBridge Wealth Partners LLC increased its holdings in shares of Cambrex by 5.2% in the 2nd quarter. YorkBridge Wealth Partners LLC now owns 1,971 shares of the biotechnology company’s stock worth $118,000 after buying an additional 97 shares during the last quarter. Mark Sheptoff Financial Planning LLC increased its holdings in shares of Cambrex by 2.5% in the 2nd quarter. Mark Sheptoff Financial Planning LLC now owns 4,000 shares of the biotechnology company’s stock worth $239,000 after buying an additional 99 shares during the last quarter. Arizona State Retirement System increased its holdings in shares of Cambrex by 0.6% in the 2nd quarter. Arizona State Retirement System now owns 16,976 shares of the biotechnology company’s stock worth $1,014,000 after buying an additional 100 shares during the last quarter. Finally, PNC Financial Services Group Inc. increased its holdings in shares of Cambrex by 0.5% in the 2nd quarter. PNC Financial Services Group Inc. now owns 22,178 shares of the biotechnology company’s stock worth $1,325,000 after buying an additional 119 shares during the last quarter.
A number of equities analysts have recently commented on CBM shares. BidaskClub lowered shares of Cambrex from a “hold” rating to a “sell” rating in a report on Thursday, August 24th. Craig Hallum reissued a “buy” rating and issued a $60.00 price target (down previously from $70.00) on shares of Cambrex in a report on Tuesday, October 31st. Finally, ValuEngine lowered shares of Cambrex from a “buy” rating to a “hold” rating in a report on Friday, September 1st. One analyst has rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the stock. The stock currently has an average rating of “Hold” and an average target price of $62.33.
Cambrex (NYSE:CBM) last announced its quarterly earnings data on Tuesday, November 7th. The biotechnology company reported $0.55 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.47 by $0.08. Cambrex had a net margin of 18.79% and a return on equity of 23.42%. The company had revenue of $112.60 million during the quarter, compared to analysts’ expectations of $108.44 million. During the same quarter in the prior year, the company earned $0.47 EPS. The firm’s revenue was up 13.4% on a year-over-year basis. analysts predict that Cambrex Co. will post 2.97 earnings per share for the current year.
In other news, CEO Steven M. Klosk sold 4,000 shares of the company’s stock in a transaction on Monday, October 2nd. The shares were sold at an average price of $54.96, for a total value of $219,840.00. Following the completion of the sale, the chief executive officer now owns 87,328 shares of the company’s stock, valued at approximately $4,799,546.88. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 2.48% of the stock is currently owned by corporate insiders.
Cambrex Company Profile
Cambrex Corporation (Cambrex) is a life sciences company. It provides products and services for the development and commercialization of generic therapeutics. It operates through four segments, which are manufacturing facilities that have been aggregated as a single segment. Its manufacturing facilities are owned by the subsidiaries, including Cambrex Charles City, Inc, Cambrex Karlskoga AB and Cambrex Profarmaco Milano S.r.l.
Receive News & Ratings for Cambrex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex and related companies with MarketBeat.com's FREE daily email newsletter.